Elizabeth Murray

Elizabeth Murray

Auto-generated profile, based on publicly available information

Elizabeth Murray

Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in American Journal of Speech-Language Pathology
Verified
Journal Article
Closed access
PDF file
EMElizabeth Murray
Elizabeth Murray
TMTricia McCabe
Tricia McCabe
KBKirrie Ballard
Kirrie Ballard
Purpose: To present a systematic review of single-case experimental treatment studies for childhood apraxia of speech (CAS). Method: A search of 9 databases was used to find peer-reviewed treatment articles from 1970 to 2012 of all levels of evidence with published communication outcomes for children with CAS. Improvement rate differences (IRDs) were calculated for articles with replicated (n > 1), statistically compared treatment and generalization evidence. Results: Forty-two articles representing Phase I and II single-case experimental designs (SCEDs; n = 23) or case series or description studies ( n = 19) were analyzed. Six articles showed high CAS diagnosis confidence. Of the 13 approaches within the 23 SCED articles, treatments were primarily for speech motor skills ( n = 6), linguistic skills ( n = 5), or augmentative and alternative communication ( n = 2). Most participants responded positively to treatment, but only 7 of 13 approaches in SCED studies reported maintenance and/or generalization of treatment effects. Three approaches had preponderant evidence (Smith, 1981). IRD effect sizes were calculated for Integral Stimulation/Dynamic Temporal and Tactile Cueing, Rapid Syllable Transition Treatment, and Integrated Phonological Awareness Intervention. Conclusions: At least 3 treatments have sufficient evidence for Phase III trials and interim clinical practice. In the future, efficacy needs to be established via maintenance and generalization measures. Supplemental Material: https://doi.org/10.23641/asha.6170225

1 February 2015 in Journal of Speech, Language, and Hearing Research
Verified
Journal Article
Closed access
PDF file
EMElizabeth Murray
Elizabeth Murray
TMTricia McCabe
Tricia McCabe
RHRobert Heard
Robert Heard
KBKirrie Ballard
Kirrie Ballard
Purpose: The gold standard for diagnosing childhood apraxia of speech (CAS) is expert judgment of perceptual features. The aim of this study was to identify a set of objective measures that differentiate CAS from other speech disorders. Method: Seventy-two children (4–12 years) diagnosed with suspected CAS by community speech-language pathologists were screened. Forty-seven participants underwent diagnostic assessment including presence/absence of perceptual CAS features. Twenty-eight children met 2 sets of diagnostic criteria for CAS (ASHA, 2007b; Shriberg, Potter & Strand, 2009); another 4 met the CAS criteria with co-morbidity. Fifteen were categorized as non-CAS with phonological impairment, submucous cleft, or dysarthria. Following this, 24 different measures from the diagnostic assessment were rated by blinded raters. Multivariate discriminant function analysis was used to identify the combination of measures that best predicted expert diagnoses. Results: The discriminant function analysis model, including syllable segregation, lexical stress matches, and percent phonemes correct from a polysyllabic picture-naming task, and articulatory accuracy on repetition of /pətəkə/, reached 91% diagnostic accuracy against expert diagnosis. Conclusions: Polysyllabic production accuracy and an oral motor examination that includes diadochokinesis may be sufficient to reliably identify CAS and rule out structural abnormality or dysarthria. Testing with a larger unselected sample is required.

1 June 2015 in Journal of Speech, Language, and Hearing Research
Verified
Journal Article
Closed access
PDF file
EMElizabeth Murray
Elizabeth Murray
TMTricia McCabe
Tricia McCabe
KBKirrie Ballard
Kirrie Ballard
Purpose: This randomized controlled trial compared the experimental Rapid Syllable Transition Treatment (ReST) to the Nuffield Dyspraxia Programme (3rd edition, NDP3), used widely in clinical practice in Australia and the United Kingdom. Both programs aim to improve speech motor planning/programming for children with apraxia of speech, but they differ in types of stimuli used, level of stimulus complexity at initiation of treatment, and the principles of motor learning that they apply. Method: Treatment was delivered to 26 children with mild to severe CAS aged 4–12 years through trained and supervised speech-language pathology students in 1-hour sessions, 4 days a week for 3 weeks at a university clinic. Articulation and prosodic accuracy were assessed at pretreatment, 1 week, 1 month, and 4 months post-treatment using blinded independent assessors to compare treatment, maintenance and generalization effects. Results: The ReST and NDP3 treatments demonstrated large treatment effects. ReST maintained treatment gains from 1 week to 4 months post-treatment more effectively than the NDP3. Significant generalization to untreated stimuli was observed for both ReST and NDP3. Conclusions: ReST and NDP3 have strong evidence of treatment and generalization gains in children with CAS when delivered intensively. Overall ReST has greater external evidence from multiple sources but both treatments have support for clinical use.

15 July 2015 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
EFEvelina Fedorenko
Evelina Fedorenko
AMAngela Morgan
Angela Morgan
EMElizabeth Murray
Elizabeth Murray
ACAnnie Cardinaux
Annie Cardinaux
CMCristina Mei
Cristina Mei
NKNancy Kanwisher
Nancy Kanwisher
Individuals with heterozygous 16p11.2 deletions reportedly suffer from a variety of difficulties with speech and language. Indeed, recent copy-number variant screens of children with childhood apraxia of speech (CAS), a specific and rare motor speech disorder, have identified three unrelated individuals with 16p11.2 deletions. However, the nature and prevalence of speech and language disorders in general, and CAS in particular, is unknown for individuals with 16p11.2 deletions. Here we took a genotype-first approach, conducting detailed and systematic characterization of speech abilities in a group of 11 unrelated children ascertained on the basis of 16p11.2 deletions. To obtain the most precise and replicable phenotyping, we included tasks that are highly diagnostic for CAS, and we tested children under the age of 18 years, an age group where CAS has been best characterized. Two individuals were largely nonverbal, preventing detailed speech analysis, whereas the remaining nine met the standard accepted diagnostic criteria for CAS. These results link 16p11.2 deletions to a highly penetrant form of CAS. Our findings underline the need for further precise characterization of speech and language profiles in larger groups of affected individuals, which will also enhance our understanding of how genetic pathways contribute to human communication disorders.

27 January 2021 in American Journal of Speech-Language Pathology
Verified
Journal Article
Closed access
EMElizabeth Murray
Elizabeth Murray
JIJenya Iuzzini-Seigel
Jenya Iuzzini-Seigel
EMEdwin Maas
Edwin Maas
HTHayo Terband
Hayo Terband
KBKirrie Ballard
Kirrie Ballard
Purpose: The aim of this study was to determine the discriminative features that might contribute to differentiation of childhood apraxia of speech (CAS) from other speech sound disorders (SSDs). Method: A comprehensive literature search was conducted for articles or doctoral dissertations that included ≥ 1 child with CAS and ≥ 1 child with SSD. Of 2,071 publications screened, 53 met the criteria. Articles were assessed for (a) study design and risk of bias; (b) participant characteristics and confidence in diagnosis; and (c) discriminative perceptual, acoustic, or kinematic measures. A criterion was used to identify promising studies: American Academy of Neurology study design (Class III+), replicable participant descriptions and adequate confidence in diagnosis (≥ 3), and ≥ 1 discriminative and reliable measure. Results: Over 75% of studies were retrospective, case–control designs and/or assessed English-speaking children. Many studies did not fully describe study design and quality. No studies met the Class I (highest) quality rating according to American Academy of Neurology guidelines. CAS was mostly compared to speech delay/phonological disorder. Only six studies had diagnostic confidence ratings of 1 (best). Twenty-six studies reported discriminative perceptual measures, 14 reported discriminative acoustic markers, and four reported discriminative kinematic markers. Measures were diverse, and only two studies directly replicated previous findings. Overall, seven studies met the quality criteria, and another eight nearly met the study criteria to warrant further investigation. Conclusions: There are no studies of the highest diagnostic quality. There are 15 studies that can contribute to further diagnostic efforts discriminating CAS from other SSDs. Future research should utilize careful diagnostic design, support replication, and adhere to standard reporting guidelines. Supplemental Material: https://doi.org/10.23641/asha.13158149

28 January 2013 in International Journal of Language & Communication Disorders
Verified
Journal Article
Closed access
PDF file
EMElizabeth Murray
Elizabeth Murray
EPEmma R. Power
Emma R. Power
LTLeanne Togher
Leanne Togher
TMTricia McCabe
Tricia McCabe
NMNatalie Munro
Natalie Munro
KSKatherine Smith
Katherine Smith